Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Endocriene therapie na borstkanker veilig te onderbreken vanwege zwangerschapswens?
jul 2023 | Borstkanker